Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1982 1
1985 2
1986 3
1987 6
1988 4
1989 4
1990 1
1991 1
1992 1
1993 1
1994 3
1995 2
1996 3
1997 5
1998 3
1999 6
2000 3
2001 4
2002 7
2003 7
2004 12
2005 17
2006 8
2007 17
2008 21
2009 13
2010 22
2011 11
2012 15
2013 20
2014 32
2015 19
2016 30
2017 35
2018 38
2019 29
2020 18
2021 38
2022 30
2023 28
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

480 results

Results by year

Filters applied: . Clear all
Page 1
Overcome the barriers of the skin: exosome therapy.
Yang GH, Lee YB, Kang D, Choi E, Nam Y, Lee KH, You HJ, Kang HJ, An SH, Jeon H. Yang GH, et al. Biomater Res. 2021 Jul 3;25(1):22. doi: 10.1186/s40824-021-00224-8. Biomater Res. 2021. PMID: 34217362 Free PMC article. Review.
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, Wang XY, Sun L, Ge NL, Huang XW, Qiu SJ, Yang XR, Gao Q, He YF, Xu Y, Sun J, Ren ZG, Fan J, Zhou J. Shi GM, et al. Among authors: yang gh. Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7. Signal Transduct Target Ther. 2023. PMID: 36928584 Free PMC article. Clinical Trial.
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J. Lu JC, et al. Among authors: yang gh. Nat Commun. 2024 Jan 20;15(1):621. doi: 10.1038/s41467-024-44795-1. Nat Commun. 2024. PMID: 38245530 Free PMC article.
3D bioprinting and its in vivo applications.
Hong N, Yang GH, Lee J, Kim G. Hong N, et al. Among authors: yang gh. J Biomed Mater Res B Appl Biomater. 2018 Jan;106(1):444-459. doi: 10.1002/jbm.b.33826. Epub 2017 Jan 20. J Biomed Mater Res B Appl Biomater. 2018. PMID: 28106947 Review.
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion.
Meng XL, Lu JC, Zeng HY, Chen Z, Guo XJ, Gao C, Pei YZ, Hu SY, Ye M, Sun QM, Yang GH, Cai JB, Huang PX, Yv L, Zhang L, Shi YH, Ke AW, Zhou J, Fan J, Chen Y, Huang XY, Shi GM. Meng XL, et al. Among authors: yang gh. Hepatol Int. 2023 Feb;17(1):63-76. doi: 10.1007/s12072-022-10445-1. Epub 2022 Nov 22. Hepatol Int. 2023. PMID: 36418844 Free PMC article.
480 results